Nephrol Dial Transplant (2002) 17: 1667-1673
© 2002 European Renal Association-European Dialysis and Transplant Association
Erythropoietin therapy may retard progression in chronic renal transplant dysfunction
Departments of Medicine and 1 Surgery, University of Wisconsin Medical School, Madison, WI 53792, USA
Background. Recent data suggests that erythropoietin therapy may actually retard the progression of chronic kidney disease (CKD). Transplant recipients with evidence of chronic allograft dysfunction could respond in a similar manner to erythropoietin.
Methods. We evaluated 166 individuals who initiated erythropoietin therapy after at least 18 days of transplant function. One hundred and nine individuals received erythropoietin between days 18 and 294 of transplant function (group 1-early epoietin alfa) while 57 individuals received erythropoietin on or after day 294 of transplant function (group 2-late epoietin alfa). The slope of serum creatinine (Scr) (
slope Scr) prior to and following the start of erythropoietin therapy and calculated glomerular filtration rates (GFR) were used to assess renal function over time.
Results. The average haematocrit rose 6.6% in group 1 patients and 2.1% in group 2 patients during the first 100 days of erythropoietin therapy. The slope Scr was not significantly altered in group 1 patients. However, for group 2 individuals who continued to have graft function (n=35), the slope Scr became negative during erythropoietin treatment. This indicated a deceleration in the rate of loss of renal function (day 200 slope Scr -0.0033, P=0.00091; day 300 slope Scr -0.0014, P=0.05; day 400 slope Scr -0.0066, N.S., P=0.066). GFR remained stable in both cohorts. Finally, group 2-late epoietin alfa patients treated with erythropoietin demonstrated a marked trend towards longer graft survival than a group of similar control patients (N.S., P=0.064).
Conclusions. The data in a group of renal transplant recipients with chronic allograft dysfunction reinforce data from the CKD realm suggesting that erythropoietin may be of benefit in slowing the rate of loss of function over time. However, this renal response is not evident in all patients. Prospective studies of erythropoietin or erythropoietin-like medications are warranted in this population to better discriminate those who may respond well to administration of these drugs.
Keywords: anaemia; erythropoietin; kidney transplantation
Correspondence and offprint requests to: Bryan N. Becker, MD, B3063 UW Nephrology, 2500 Overlook Terrace, Madison, WI 53705, USA. Email: bnb{at}medicine.wisc.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. C. Winkelmayer, A. Chandraker, M. Alan Brookhart, R. Kramar, and G. Sunder-Plassmann A prospective study of anaemia and long-term outcomes in kidney transplant recipients Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3559 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Imoagene-Oyedeji, S. E. Rosas, A. M. Doyle, S. Goral, and R. D. Bloom Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3240 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Djamali, M. Samaniego, B. Muth, R. Muehrer, R. M. Hofmann, J. Pirsch, A. Howard, G. Mourad, and B. N. Becker Medical Care of Kidney Transplant Recipients after the First Posttransplant Year Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 623 - 640. [Abstract] [Full Text] [PDF]
|
|